Company Analysis
Sign in

Novavax, Inc. (NVAX)

Nasdaq: NVAX · Biological Products, (No Diagnostic Substances) · Gaithersburg, MD · filing with the SEC since 1996
Full chart Alerts Compare
Grade5.5
◀ Past 5.3● Present 5.7▶ Future 5.6
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

61 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Novavax, Inc.’s names, not what it holds today.

Patents granted
61
61 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and 1 in 2023
Applications published
80
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals12
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Novavax, Inc. its own name
US, as the owner printed on each patent
61 granted
23 published
NOVAVAX, INC. its own name
named as the applicant on its applications, in US. 16 more under the same name are not counted (printed in SE)
0 granted
57 published
Names not counted (1)
NOVAVAX INC
Most of its patents print SE; this name counts in US. 7 granted and 4 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 26, 202411,938,179Methods and compositions for inducing immune responses against Clostridium difficilePharmaceuticalsNovavax, Inc.
Feb 13, 202411,896,664Corona virus vaccine formulationsPharmaceuticalsNovavax, Inc.
Feb 13, 202411,896,662Multivalent influenza nanoparticle vaccinesPharmaceuticalsNovavax, Inc.
Jan 3, 202311,541,112Coronavirus vaccine formulationsPharmaceuticalsNovavax, Inc.
Sep 20, 202211,446,374Modified RSV F proteins and methods of their usePharmaceuticalsNovavax, Inc.
Jun 21, 202211,364,294Vaccine compositions having improved stability and immunogenicityPharmaceuticalsNovavax, Inc.
Mar 22, 202211,278,612Multivalent influenza nanoparticle vaccinesPharmaceuticalsNovavax, Inc.
Feb 22, 202211,253,586Coronavirus vaccine formulationsPharmaceuticalsNovavax, Inc.
Feb 22, 202211,253,585Vaccine compositions having improved stability and immunogenicityPharmaceuticalsNovavax, Inc.
Sep 21, 202111,123,419Methods and compositions for inducing immune responses against Clostridium difficilePharmaceuticalsNovavax, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0325646COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST EPSTEIN-BARR VIRUSPharmaceuticalsNOVAVAX, INC.
Sep 4, 20252025/0276054AVIAN INFLUENZA NANOPARTICLE IMMUNOGENIC COMPOSITIONSPharmaceuticalsNOVAVAX, INC.
May 8, 20252025/0144200INTRANASAL IMMUNOGENIC COMPOSITIONSPharmaceuticalsNOVAVAX, INC.
Apr 3, 20252025/0109187ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19Analysis of biological materialsNOVAVAX, INC.
Mar 13, 20252025/0085282METHOD FOR DETECTING ANTI-SARS-COV-2 SPIKE (S) IMMUNOGLOBULINSAnalysis of biological materialsNOVAVAX, INC.
Feb 27, 20252025/0066456ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19BiotechnologyNOVAVAX, INC.
Jan 23, 20252025/0025549CORONAVIRUS VACCINE FORMULATIONSPharmaceuticalsNOVAVAX, INC.
Dec 26, 20242024/0423926METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASEPharmaceuticalsNOVAVAX, INC.
Dec 19, 20242024/0415947MALARIA VACCINE FORMULATIONSPharmaceuticalsNOVAVAX, INC.
Dec 12, 20242024/0408187METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIAPharmaceuticalsNOVAVAX, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Biotechnology 2 · Analysis of biological materials 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NVAX · research, not advice